Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Long-Term Investments (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Long-Term Investments for 8 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 16.84% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2025, down 16.84%, and an annual FY2025 reading of $1.9 million, down 16.84% over the prior year.
  • Long-Term Investments was $1.9 million for Q4 2025 at Abvc Biopharma, down from $2.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $2.8 million in Q2 2025 and bottomed at $816160.0 in Q3 2022.
  • Average Long-Term Investments over 5 years is $1.7 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Long-Term Investments crashed 50.12% in 2021, then skyrocketed 228.05% in 2023.
  • Year by year, Long-Term Investments stood at $932755.0 in 2021, then decreased by 9.72% to $842070.0 in 2022, then skyrocketed by 200.18% to $2.5 million in 2023, then fell by 10.64% to $2.3 million in 2024, then dropped by 16.84% to $1.9 million in 2025.
  • Business Quant data shows Long-Term Investments for ABVC at $1.9 million in Q4 2025, $2.7 million in Q3 2025, and $2.8 million in Q2 2025.